Levalbuterol 0,31 Mg/ 3 Ml, 0,63 Mg/ 3 Ml & 1,25 Mg/ 3 Ml Cipla 0,31 mg, 0,63 mg, 1,25 mg Inhalation solution
PDF Leaflet Revision Date: 04 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of reversible airway obstruction in asthma and bronchospasm prevention.
Dosage (summary)
Adults: 0.63 mg/3 mL thrice daily; max 1.25 mg/3 mL if needed. Children 6-11: 0.31 mg/3 mL thrice daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not adequately studied in pregnancy; use with caution. Unknown safety in breastfeeding.
Key Drug Interactions
- Other sympathomimetics
- Beta-blockers
- Diuretics
- Digoxin
- MAOIs
- Tricyclic antidepressants
Contraindications
- Hypersensitivity to levalbuterol or components
- Children under 6 years
Common side effects
- Dizziness
- Tachycardia
- Nervousness
- Insomnia
- Hypersensitivity reactions
Counselling Points
- Monitor for worsening asthma
- Avoid exceeding recommended dose
- Report any hypersensitivity reactions
Serious warnings
- Paradoxical bronchospasm
- Asthma deterioration
- Cardiovascular effects
- Hypokalaemia risk
Important Disclaimer
The Levalbuterol 0,31 Mg/ 3 Ml, 0,63 Mg/ 3 Ml & 1,25 Mg/ 3 Ml Cipla 0,31 mg, 0,63 mg, 1,25 mg Inhalation solution professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
